On Monday, AtriCure Inc. (NASDAQ:ATRC)’s shares declined -8.82% to $20.47.
AtriCure, Inc. ( ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage administration, declared that it has reached a definitive merger agreement under which AtriCure has agreed to acquire n Contact, Inc., a privately held developer of innovative cardiac ablation solutions.
The transaction consideration comprises of an upfront payment of about 3.7 million shares of AtriCure common stock, valued at $24.60 per share, and about $8 million in cash, subject to closing adjustments. The transaction also comprises up to $50 million in additional contingent consideration based on completion of enrollment of the CONVERGE IDE trial and PMA approval. Additionally, nContact shareholders are entitled to additional sales-based contingent consideration on revenue in excess of an annual growth rate of greater than 25% through 2019. All contingent consideration can be paid in either cash or AtriCure common stock, or a combination of both.
AtriCure, Inc., a medical device company, provides atrial fibrillation solutions worldwide. The company offers Isolator Synergy ablation system and related radio frequency(RF) ablation devices, which comprise clamps that are used for ablation during open-heart procedures; and Coolrail linear ablation device, a disposable linear RF ablation device that allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures.
Theravance Inc (NASDAQ:THRX)’s shares gained 8.41% to $9.28.
GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) declared data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001), from an exploratory post-hoc analysis of phase III data, which showed that patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who received Anoro® Ellipta® (UMEC/VI 62.5/25mcg) had a reduced risk of experiencing a clinically important deterioration contrast to tiotropium 18mcg or placebo over a 12-week treatment period.
This post-hoc analysis used a novel, composite endpoint, defined as a clinically important deterioration, to assess the effect of treatment on a number of factors that are each believed to represent a worsening of a patient’s COPD. The analysis examined the time to a first clinically important deterioration which was determined by the occurrence of any of the following events: A decrease in lung function of ≥100 ml from baseline as measured by trough FEV1; a deterioration in health-related quality of life defined as ≥4 unit enhance from baseline in St George’s Respiratory Questionnaire (SGRQ) total score; or the occurrence of an on-treatment moderate-to-severe COPD exacerbation.
Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK).
At the end of Monday’s trade, Pioneer Energy Services Corp (NYSE:PES)‘s shares surged 11.82% to $2.46.
Pioneer Energy Services (PES) declared that it will release its third quarter 2015 financial results before the market opens on Thursday, October 29. In conjunction with the release, Pioneer has planned a conference call that will be broadcast live over the Internet the same day starting at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Investors may take part in the call either by phone or audio webcast.
Pioneer Energy Services Corp., through its auxiliaries, provides drilling services and production services to oil and gas exploration and production companies in the United States and Colombia.
Simon Property Group Inc (NYSE:SPG), ended its Monday’s trading session with 2.26% gain, and closed at $191.71.
Simon Brand Ventures, the media sales arm of Simon Property Group, declared recently that it will become the exclusive sales agent of the popular Backlit Ad Panels at 122 Simon® shopping centers. Forty-eight centers will transition January 1, 2016; 19 centers on April 1, 2016; 52 centers on June 1, 2016; and the remaining three centers on July 26, 2016.
Many iconic Simon properties are part of the transition, counting The Galleria (Houston), Lenox Square (Atlanta), Fashion Center at Pentagon City (Washington, DC), Copley Place (Boston), Dadeland Mall (Miami), The Shops at Mission Viejo (Los Angeles / Orange County), Roosevelt Field (NYC), and King of Prussia (Philadelphia), among others.
Simon Property Group, Inc. is an equity real estate investment trust. The firm invests in the real estate markets across the globe. It engages in investment, ownership, management, and development of properties.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
